Published: Monday, June 23, 2025 · 1:45 PM | Updated: Monday, June 23, 2025 · 1:45 PM
📊 286 views
- VSee Health, Inc. (VSEE, Financial) is spearheading a Phase 3 NIH-funded stroke recovery study utilizing its telerehabilitation platform.
- The study, conducted across 29 hospitals, aims to improve arm function in stroke survivors, impacting a $328M global market.
- VSee’s involvement positions the company as a leader in cost-effective, value-based virtual neurorehabilitation solutions.
VSee Health, Inc. (VSEE), a prominent provider of digital health solutions, has been chosen to support a major NIH-funded Phase 3 clinical trial focused on stroke recovery through telerehabilitation. The study, which is a collaborative initiative with UCLA, involves 202 patients across 29 hospitals and evaluates the efficacy of a six-week gamified, home-based telerehabilitation program aimed at enhancing arm functionality in stroke survivors.
This trial is significant as it could lead to Medicare and private payer reimbursement in the $328 million global stroke rehabilitation market, underscoring telehealth’s potential to disrupt traditional therapy models. Dr. Steven Cramer, MD, a UCLA neurology professor and trial co-principal investigator, emphasized the crucial role of VSee’s HIPAA-compliant platform in providing secure and seamless intervention delivery, essential for compliance and engagement in the large-scale trial.
Dr. Milton Chen, PhD, Co-CEO of VSee Health, expressed pride in the company’s role in this groundbreaking trial, highlighting the validation it provides for telehealth as a scalable, cost-efficient model in neurorehabilitation. The trial’s success could pave the way for gamified telerehabilitation applications in other neurological conditions like multiple sclerosis and traumatic brain injuries.
The trial begins patient enrollment in Q3 2025, offering a combination of independent and therapist-supervised exercises that leverage VSee’s platform to overcome common barriers to traditional physical therapy, such as limited clinic access and poor patient motivation. This development further cements VSee’s position as an innovative player in the telerehab space.
MORE IN INSIDE INVESTMENT NEWS
CVS earnings Surge: Why This Turnaround is a Portfolio Game-Changer
Published: Wednesday, August 5, 2026 · 11:39 AM
Eli Lilly quarterly estimates Surge on Explosive GLP-1 Demand
Published: Wednesday, August 5, 2026 · 11:38 AM
